Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,150,973 papers from all fields of science
Search
Sign In
Create Free Account
elbasvir / grazoprevir
Known as:
ELBASVIR/GRAZOPREVIR
, elbasvir and grazoprevir
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
elbasvir
grazoprevir
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir
W. Ankrom
,
R. Sanchez
,
+8 authors
S. Khalilieh
Antimicrobial Agents and Chemotherapy
2019
Corpus ID: 73495169
Doravirine is a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1…
Expand
2019
2019
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
Youn Jae Lee
,
J. Heo
,
+9 authors
P. Hwang
Clinical and Molecular Hepatology
2019
Corpus ID: 167218623
Background/Aims In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The…
Expand
2019
2019
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse
T. Papaluca
,
M. Sinclair
,
+11 authors
A. Thompson
Liver international (Print)
2019
Corpus ID: 198965222
Despite highly effective direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection, some patients…
Expand
2019
2019
Adjuvant ribavirin and longer direct‐acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure
Mei Lu
,
Kuan-Han H Wu
,
+10 authors
S. Gordon
Journal of Viral Hepatitis
2019
Corpus ID: 189814220
The role of ribavirin (RBV) in the era of direct‐acting antivirals (DAA) is not clear, and DAA studies have been largely genotype…
Expand
Review
2018
Review
2018
Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.
D. Chute
,
R. Chung
,
M. Sise
Kidney International
2018
Corpus ID: 3525077
2018
2018
Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China
Pingyu Chen
,
A. Ma
,
Qiang Liu
Clinical drug investigation
2018
Corpus ID: 52172405
Background and ObjectiveNew direct-acting antivirals (DAAs) have high efficacy and tolerability in the treatment of hepatitis C…
Expand
2018
2018
Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
Y. Takeuchi
,
N. Akuta
,
+11 authors
H. Kumada
Hepatology Research
2018
Corpus ID: 52051789
Treatment with all‐oral direct‐acting antiviral agents (DAAs) elbasvir/grazoprevir (EBR/GZR) is associated with high sustained…
Expand
Highly Cited
2017
Highly Cited
2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
I. Jacobson
,
E. Lawitz
,
+8 authors
B. Haber
Gastroenterology
2017
Corpus ID: 206245394
BACKGROUND & AIMS Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and…
Expand
2017
2017
Cost‐effectiveness of elbasvir/grazoprevir use in treatment‐naive and treatment‐experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States
E. Elbasha
,
W. Greaves
,
D. Roth
,
C. Nwankwo
Journal of Viral Hepatitis
2017
Corpus ID: 37112475
Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality…
Expand
Highly Cited
2016
Highly Cited
2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
J. Sperl
,
G. Horváth
,
+19 authors
H. Platt
Journal of Hepatology
2016
Corpus ID: 4965074
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE